Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection

Hepatology Research

Volumn 39, Issue 12, 2009, Pages 1159-1168

  Abe, Hiromi ^a,b,c   Ochi, Hidenori ^a,b,c   Maekawa, Toshiro ^a,c   Hatakeyama, Tsuyoshi ^b   Tsuge, Masataka ^a,c,d   Kitamura, Shosuke ^b   Kimura, Takashi ^b   Miki, Daiki ^b   Mitsui, Fukiko ^b   Hiraga, Nobuhiko ^a,b,c   Imamura, Michio ^a,b,c   Fujimoto, Yoshifumi ^a,b,c   Takahashi, Shoichi ^a,b,c   Nakamura, Yusuke ^a   Kumada, Hiromitsu ^e   Chayama, Kazuaki ^a,b,c  

^a RIKEN   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c Liver Research Project Center   (Japan)

^d HIROSHIMA UNIVERSITY   (Japan)

^e TORANOMON HOSPITAL   (Japan)

Author keywords

APOBEC3A; APOBEC3B; APOBEC3G; Deaminase; Hypermutation; Structural variation

Indexed keywords

CYTIDINE DEAMINASE; MESSENGER RNA; PROTEIN APOBEC3A; PROTEIN APOBEC3B; UNCLASSIFIED DRUG; VIRUS DNA;

ADENO ASSOCIATED VIRUS; ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CHRONIC DISEASE; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC TRANSFECTION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; LIVER FIBROSIS; LONG TERMINAL REPEAT; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; RETROPOSON; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS GENOME; WESTERN BLOTTING;

EID: 73849083952     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00566.x     Document Type: Article

References (33)

1. Jarmuz A, Chester A, Bayliss J et al. An anthropoid-specific locus of orphan c to u rnaediting enzymes on chromosome 22. Genomics 2002; 79: 285-96.
2. Wedekind JE, Dance GS, Sowden MP, Smith HC. Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. Trends Genet 2003; 19: 207-16.
3. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418: 646- 50.
4. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, Malim MH. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol 2004; 14: 1392-96.
5. Liddament MT, Brown WL, Schumacher AJ, Harris RS. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol 2004; 14: 1385-91.
6. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J 2004; 23: 2451-8.
7. Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, Peterlin BM. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol 2004; 78: 6073-6.
8. Dang Y, Wang X, Esselman WJ, Zheng YH. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J Virol 2006; 80: 10522-33.
9. Cullen BR. Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J. Virol 2006; 80: 1067-76.
10. Chen H, Lilley CE, Yu Q et al. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr Biol 2006; 16: 480-5.
11. Bogerd HP, Wiegand HL, Doehle BP, Lueders KK, Cullen BR. APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res 2006; 34: 89-95.
12. Bogerd HP, Wiegand HL, Hulme AE et al. Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc Natl Acad Sci USA 2006; 103: 8780-5.
13. Chen H, Lilley CE, Yu Q et al. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr Biol 2006; 16: 480-5.
14. Turelli P, Mangeat B, Jost S, Vianin S, Trono D. Inhibition of hepatitis B virus replication by APOBEC3G. Science [2004;] 303: 1829.
15. Rösler C, Köck J, Malim MH, Blum HE, von Weizsäcker F. Comment on "inhibition of hepatitis B virus replication by APOBEC3G". Science 2004; 305: 1403a.
16. Turelli P, Jost S, Mangeat B, Trono D. Response to comment on "inhibition of hepatitis B virus replication by APOBEC3G". Science 2004; 305: 1403b.
17. Noguchi C, Ishino H, Tsuge M et al. G to A hypermutation of hepatitis B virus. Hepatology 2005; 41: 626-33.
18. Suspène R, Guétard D, Henry M, Sommer P, Wain-Hobson S, Vartanian JP. Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci 2005; 102: 8321-6.
19. Bonvin M, Achermann F, Greeve I et al. Interferoninducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 2006; 43: 1364-74.
20. Xu R, Zhang X, Zhang W, Fang Y, Zheng S, Yu XF. Association of human APOBEC3 cytidine deaminases with the generation of hepatitis virus B x antigen mutants and hepatocellular carcinoma. Hepatology 2007; 46: 1810- 20.
21. Jost S, Turelli P, Mangeat B, Protzer U, Trono D. Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons. J Virol 2007; 81: 10588-96.
22. Bonvin M, Greeve J. Effects of point mutations in the cytidine deaminase domains of APOBEC3B on replication and hypermutation of hepatitis B virus in vitro. J Gen Virol 2007; 88: 3270-4.
23. Zhang W, Zhang X, Tian C et al. Cytidine deaminase APOBEC3B interacts with heterogeneous nuclear ribonucleoprotein K and suppresses hepatitis B virus expression. Cell Microbiol 2008; 10: 112-21.
24. Henry M, Guétard D, Suspène R, Rusniok C, Wain-Hobson S, Vartanian JP. Genetic editing of HBV DNA by monodomain human APOBEC3 cytidine deaminases and the recombinant nature of APOBEC3G. PLoS ONE 2009; 4: e4277.
25. Kidd JM, Newman TL, Tuzun E, Kaul R, Eichler EE. Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genet 2007; 3: e63.
26. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
27. Price PM, Banerjee R, Jeffrey AM, Acs G. The mechanism of inhibition of hepatitis B virus replication by the carbocyclic analog of 2′-deoxyguanosine. Hepatology 1992; 16: 8-12.
28. Ohnishi Y, Tanaka T, Ozaki K, Yamada R, Suzuki H, Nakamura Y. A high-throughput SNP typing system for genome-wide association studies. J Hum Genet 2001; 46: 471-7.
29. Kobayashi M, Takaori-Kondo A, Shindo K, Abudu A, Fukunaga K, Uchiyama T. APOBEC3G targets specific virus species. J Virol 2004; 78: 8238-44.
30. Tsuge M, Hiraga N, Takaishi H et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology 2005; 42: 1046-54.
31. Noguchi C, Hiraga N, Mori N et al. Dual effect of APOBEC3G on hepatitis B virus. J Gen Virol 2007; 88: 432-40.
32. Nielsen DM, Ehm MG, Weir BS. Detecting marker-disease association by testing for Hardy-Weinberg disequilibrium at a marker locus. Am J Hum Genet 1998; 63: 1531-40.
33. Noguchi C, Imamura M, Tsuge M et al. G to A hypermutation in hepatitis B virus and clinical course of patients with chronic hepatitis B. J Inf Dis 2009; 199: 1599-607.